Skip to main content
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital. 
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-ge

Dr. John Cush RheumNow

3 years 3 months ago
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/CeLTCbB2nO https://t.co/qYXt8gCHjd
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w

Dr. John Cush RheumNow

3 years 3 months ago
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w/ a 2 fold higher risk of freq knee pain & OR 1.86 of freq intermit/constant pain. IA mineralz. meniscus or Jt capsule=higher odds of pain https://t.co/CacJ40DVyL https://t.co/Zhwv98d6Pe
Since the end of COVID, how often do you see Pharma Sales Reps (PSRs)?

Dr. John Cush RheumNow

3 years 3 months ago
Since the end of COVID, how often do you see Pharma Sales Reps (PSRs)?
Scleroderma – Thick and Thin

This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alope

Dr. John Cush RheumNow

3 years 3 months ago
Scleroderma – Thick and Thin This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy. https://t.co/IF5c8MF1zk https://t.co/zhwR4SofHt
In Memoriam: Dr. K. Frank Austen (1928-2023)

Rheumatology mourns the loss of a historic leader in the field, Dr. K. Fr

Dr. John Cush RheumNow

3 years 3 months ago
In Memoriam: Dr. K. Frank Austen (1928-2023) Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95. https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Scary Outcomes with Systemic Sclerosis Sine Scleroderma

The hallmark of SSc is scleroderma, but less than 10% of SSc p

Dr. John Cush RheumNow

3 years 3 months ago
Scary Outcomes with Systemic Sclerosis Sine Scleroderma The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc. https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY
Opioids Ineffective in Acute Lower Back and Neck Pain

A randomised controlled trial including 347 participants with lo

Dr. John Cush RheumNow

3 years 3 months ago
Opioids Ineffective in Acute Lower Back and Neck Pain A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo. https://t.co/96mETyhKyL https://t.co/48ojNCnoZW
Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary international

Dr. John Cush RheumNow

3 years 3 months ago
Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary internationally-renowned rheumatologist Dr. had a nearly 50 year career at UConn Health retiring in 2016. She passed away on Sunday, July 2. https://t.co/jUESbCySRR https://t.co/50inpx7xRW
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/D

Dr. John Cush RheumNow

3 years 3 months ago
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED

Dr. John Cush RheumNow

3 years 3 months ago
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/uKArtikNMu
RT @drdavidliew : Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the

Dr. John Cush RheumNow

3 years 3 months ago
RT @drdavidliew : Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK https://t.co/RuPZ0ys0xW
RT @bella_mehta : An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections an

Dr. John Cush RheumNow

3 years 3 months ago
RT @bella_mehta : An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts #EULAR2023
RT @Janetbirdope : What would you do? A middle aged woman has pain and impaired hand function with her PIP&DIP erosi

Dr. John Cush RheumNow

3 years 3 months ago
RT @Janetbirdope : What would you do? A middle aged woman has pain and impaired hand function with her PIP&DIP erosive hand #osteoarthritis? Exam - jts are tender w soft tissue swelling? #NSAIDs, #denosumab, #methotrexate? 🤷‍♀️ A +RCT of #MTX in #erosive #hand #OA at #EULAR2023
×